See more : Medical System Network Co., Ltd. (4350.T) Income Statement Analysis – Financial Results
Complete financial analysis of Arcadia Biosciences, Inc. (RKDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcadia Biosciences, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
You may be interested
- Nanobiotix S.A. (NANO.PA) Income Statement Analysis – Financial Results
- RingCentral, Inc. (0V50.L) Income Statement Analysis – Financial Results
- Intact Financial Corporation (IFTPF) Income Statement Analysis – Financial Results
- Blackstone Loan Financing Limited (BGLF.L) Income Statement Analysis – Financial Results
- Bravo Enterprises Ltd. (OGNG) Income Statement Analysis – Financial Results
Arcadia Biosciences, Inc. (RKDA)
About Arcadia Biosciences, Inc.
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.33M | 9.96M | 6.78M | 8.03M | 1.17M | 1.46M | 4.03M | 3.19M | 5.41M | 6.98M | 6.48M | 7.01M |
| Cost of Revenue | 3.30M | 9.80M | 8.71M | 5.20M | 885.00K | 661.00K | 283.00K | 895.00K | 892.00K | 2.00M | 673.00K | 909.00K |
| Gross Profit | 2.03M | 154.00K | -1.93M | 2.84M | 284.00K | 803.00K | 3.74M | 2.29M | 4.52M | 4.99M | 5.81M | 6.10M |
| Gross Profit Ratio | 38.09% | 1.55% | -28.44% | 35.29% | 24.29% | 54.85% | 92.97% | 71.93% | 83.52% | 71.40% | 89.61% | 87.03% |
| Research & Development | 1.39M | 1.51M | 3.89M | 7.96M | 7.10M | 6.07M | 7.41M | 8.66M | 8.97M | 10.01M | 8.40M | 7.95M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 16.47M | 13.57M | 11.60M | 10.65M | 12.25M | 11.12M | 10.13M | 7.97M | 8.28M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.51M | 18.05M | 22.94M | 16.47M | 13.57M | 11.60M | 10.65M | 12.25M | 11.12M | 10.13M | 7.97M | 8.28M |
| Other Expenses | 73.00K | 33.00K | 10.11M | 105.00K | 466.00K | -3.61M | 281.00K | 340.00K | 521.00K | 0.00 | 5.00K | 8.00K |
| Operating Expenses | 15.90M | 19.56M | 26.83M | 24.43M | 20.67M | 17.67M | 18.06M | 20.91M | 20.09M | 20.14M | 16.37M | 16.23M |
| Cost & Expenses | 19.27M | 29.36M | 35.54M | 29.63M | 21.55M | 18.33M | 18.34M | 21.81M | 20.98M | 22.14M | 17.04M | 17.14M |
| Interest Income | 695.00K | 289.00K | 20.00K | 47.00K | 5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 289.00K | 20.00K | 47.00K | 5.00K | 0.00 | 747.00K | 1.32M | 2.66M | 1.39M | 626.00K | 186.00K |
| Depreciation & Amortization | 287.00K | 1.36M | 1.04M | 662.00K | 194.00K | 154.00K | 279.00K | 304.00K | 294.00K | 358.00K | 391.00K | 378.00K |
| EBITDA | -13.58M | -13.65M | -23.27M | -5.44M | -28.67M | -13.32M | -14.66M | -17.98M | -14.98M | -15.39M | -10.17M | -9.74M |
| EBITDA Ratio | -254.75% | -228.21% | -270.87% | -259.21% | -1,747.56% | -1,562.64% | -341.65% | -563.86% | -272.40% | -211.90% | -156.99% | -139.00% |
| Operating Income | -13.94M | -19.40M | -35.53M | -21.59M | -20.38M | -16.87M | -14.32M | -18.62M | -15.56M | -15.15M | -10.57M | -10.13M |
| Operating Income Ratio | -261.50% | -194.89% | -523.98% | -268.76% | -1,743.46% | -1,152.32% | -355.56% | -584.07% | -287.46% | -217.03% | -163.11% | -144.51% |
| Total Other Income/Expenses | 781.00K | 3.19M | 19.39M | 6.63M | -9.49M | 3.40M | -1.37M | -979.00K | -2.37M | -1.99M | -621.00K | -178.00K |
| Income Before Tax | -13.16M | -15.60M | -16.13M | -6.15M | -28.87M | -13.47M | -15.68M | -19.60M | -17.93M | -17.14M | -11.19M | -10.31M |
| Income Before Tax Ratio | -246.85% | -156.67% | -237.94% | -76.55% | -2,469.72% | -920.08% | -389.49% | -614.77% | -331.18% | -245.55% | -172.69% | -147.05% |
| Income Tax Expense | 8.00K | 14.00K | 2.00K | -124.00K | 2.00K | 10.00K | 26.00K | 25.00K | 26.00K | 263.00K | 167.00K | 213.00K |
| Net Income | -13.98M | -15.61M | -16.13M | -6.03M | -28.87M | -13.48M | -15.71M | -19.62M | -17.96M | -18.34M | -13.20M | -12.37M |
| Net Income Ratio | -262.31% | -156.81% | -237.96% | -75.01% | -2,469.89% | -920.77% | -390.14% | -615.56% | -331.66% | -262.66% | -203.69% | -176.46% |
| EPS | -11.30 | -26.05 | -30.33 | -24.20 | -181.50 | -143.16 | -291.38 | -353.85 | -503.00 | -448.39 | -322.62 | -302.44 |
| EPS Diluted | -11.30 | -26.05 | -30.33 | -24.20 | -181.50 | -143.16 | -291.38 | -353.85 | -503.00 | -448.39 | -322.62 | -302.44 |
| Weighted Avg Shares Out | 1.24M | 599.39K | 532.02K | 248.98K | 159.08K | 94.16K | 53.91K | 55.46K | 35.70K | 40.90K | 40.90K | 40.90K |
| Weighted Avg Shares Out (Dil) | 1.24M | 599.39K | 532.02K | 248.98K | 159.08K | 94.16K | 53.91K | 55.46K | 35.70K | 40.90K | 40.90K | 40.90K |
Arcadia Biosciences (RKDA) Q4 Earnings Beat Mark, Sales Up Y/Y
Arcadia Biosciences (RKDA) reports improved top-line results in the fourth quarter of 2023, which is aided by higher GoodWheat and GLA revenues.
Arcadia Biosciences, Inc. (RKDA) Q4 2023 Earnings Call Transcript
Arcadia Biosciences, Inc. (RKDA) Q4 2023 Earnings Call Transcript
Arcadia Biosciences (RKDA) Reports Q4 Loss, Misses Revenue Estimates
Arcadia Biosciences (RKDA) came out with a quarterly loss of $2.48 per share versus the Zacks Consensus Estimate of a loss of $2.68. This compares to loss of $6.31 per share a year ago.
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2023 Financial Results and Business Highlights
DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the fourth quarter and full year of 2023. “We are now at the halfway point...
Arcadia Biosciences (RKDA) Announces Date of Fourth Quarter 2023 Financial Results and Business Highlights Conference Call
DALLAS--(BUSINESS WIRE)--Arcadia Biosciences Inc. (RKDA) will announce its fourth quarter and full year 2023 financial results on March 28, 2024 at 4:30PM ET.
Arcadia Biosciences (RKDA) Expands GoodWheat™ Mac & Cheese with Nationwide Availability
DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, has expanded the availability of its better-for-you, high fiber GoodWheat™ Mac & Cheese, making the sneaky delicious product available to consumers nationwide on...
5 Agriculture - Products Stocks to Watch in a Challenging Industry
The Zacks Rank for the Agriculture - Products industry paints a gloomy picture. Investors should keep an eye on these five stocks braving the industry headwinds -- West Fraser (WFG), CalMaine Foods (CALM), GrowGeneration (GRWG), Hydrofarm (HYFM) and Arcadia Biosciences...
3 Agriculture - Products Stocks to Watch in a Promising Industry
The Agriculture - Products industry is set to gain from solid demand. Stocks like Bunge (BG), Andersons (ANDE) and Arcadia Biosciences (RKDA) are poised to ride on this positive trend.
Arcadia Biosciences, Inc. (RKDA) Q3 2023 Earnings Call Transcript
Arcadia Biosciences, Inc. (NASDAQ:RKDA ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants T.J. Schaefer - Chief Financial Officer Stan Jacot - President and Chief Executive Officer Conference Call Participants Dipesh Patel - H.C.
Arcadia Biosciences (RKDA) Announces Strong Third Quarter 2023 Financial Results and Business Highlights
DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the third quarter of 2023. “Arcadia continues to make excellent progress in executing Project Greenfield,...
Source: https://incomestatements.info
Category: Stock Reports